The veteran psilocybin PTSD pilot paper generates no FDA advisory committee scheduling or Type B meeting announcement before end of Q3 2026.

A small, early-stage study on psilocybin (the active compound in 'magic mushrooms') for veterans with PTSD (post-traumatic stress disorder) won't be enough to get the FDA (the US drug regulator) to schedule formal review meetings by the end of September 2026. Early studies that lack a control group — meaning no comparison group of patients — simply don't meet the bar regulators need to take official action. Real people won't see any new treatment options move forward based on this study alone.

Open-label pilots don't trigger regulatory milestones; controlled data is prerequisite. My role demands rigor over urgency.